In support of this finding, the anti-tumor effect of CXCL12 was reduced in pfp-/- mice and in TRAIL-/- mice, suggesting that the CD8+ T cells exert their effects via the death receptor pathway as well as the granule exocytosis pathway. The gene discussed is TNFSF10; the disease is neoplasm.